Unknown

Dataset Information

0

RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening and human myofiber dynamic Ca2+ assays.


ABSTRACT: Elevated cytoplasmic [Ca2+] is characteristic in severe skeletal and cardiac myopathies, diabetes, and neurodegeneration, and partly results from increased Ca2+ leak from sarcoplasmic reticulum stores via dysregulated ryanodine receptor (RyR) channels. Consequently, RyR is recognized as a high-value target for drug discovery to treat such pathologies. Using a FRET-based high-throughput screening assay that we previously reported, we identified small-molecule compounds that modulate the skeletal muscle channel isoform (RyR1) interaction with calmodulin and FK506 binding protein 12.6. Two such compounds, chloroxine and myricetin, increase FRET and inhibit [3H]ryanodine binding to RyR1 at nanomolar Ca2+. Both compounds also decrease RyR1 Ca2+ leak in human skinned skeletal muscle fibers. Furthermore, we identified compound concentrations that reduced leak by >?50% but only slightly affected Ca2+ release in excitation-contraction coupling, which is essential for normal muscle contraction. This report demonstrates a pipeline that effectively filters small-molecule RyR1 modulators towards clinical relevance.

SUBMITTER: Rebbeck RT 

PROVIDER: S-EPMC7000700 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening and human myofiber dynamic Ca<sup>2+</sup> assays.

Rebbeck Robyn T RT   Singh Daniel P DP   Janicek Kevyn A KA   Bers Donald M DM   Thomas David D DD   Launikonis Bradley S BS   Cornea Razvan L RL  

Scientific reports 20200204 1


Elevated cytoplasmic [Ca<sup>2+</sup>] is characteristic in severe skeletal and cardiac myopathies, diabetes, and neurodegeneration, and partly results from increased Ca<sup>2+</sup> leak from sarcoplasmic reticulum stores via dysregulated ryanodine receptor (RyR) channels. Consequently, RyR is recognized as a high-value target for drug discovery to treat such pathologies. Using a FRET-based high-throughput screening assay that we previously reported, we identified small-molecule compounds that  ...[more]

Similar Datasets

| S-EPMC10088286 | biostudies-literature
| S-EPMC5107933 | biostudies-literature
| S-EPMC10082157 | biostudies-literature
| S-EPMC1626092 | biostudies-literature
| S-EPMC7202896 | biostudies-literature
| S-EPMC5567428 | biostudies-literature
| S-EPMC5506495 | biostudies-literature
| S-EPMC7506572 | biostudies-literature
| S-EPMC4356983 | biostudies-other
| S-EPMC6423007 | biostudies-literature